It has been shown that the energy of helium-neonium laser does not affect the tracheal and bronchial mucosa and does not induce tissue irreversible changes under the dose of 358 J/cm2. The sufficient parameters for good treatment are: -4.78 J/cm2, the density of power--7.9 mWt/cm2, the power--0.6 J and time of exposition -1 min.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Application value of using a SaCo videolaryngeal mask airway combined with a bronchial blocker in patients undergoing minimally invasive thoracoscopic surgery.
Am J Transl Res
December 2024
Department of Anesthesiology, Xidian Group Hospital Xi'an 710077, Shaanxi, China.
Objective: To investigate the efficacy of the SaCo videolaryngeal mask airway (VLMA) in combination with a bronchial blocker in patients undergoing minimally invasive thoracoscopic surgery.
Methods: A retrospective analysis was conducted on the clinical data of 120 patients who underwent minimally invasive thoracoscopic surgery from January 2022 to December 2023. Patients were grouped based on their treatment methods: 68 patients who received the SaCo VLMA combined with a bronchial blocker intraoperatively were designated as the L group, while 52 patients who received a tracheal tube combined with a bronchial blocker intraoperatively were designated as the E group.
Optimization of a micro-scale air-liquid-interface model of human proximal airway epithelium for moderate throughput drug screening for SARS-CoV-2.
Respir Res
January 2025
Department of Pediatrics, David Geffen School of Medicine, UCLA Children's Discovery and Innovation Institute, Mattel Children's Hospital UCLA, UCLA, Los Angeles, CA, 90095, USA.
Background: Many respiratory viruses attack the airway epithelium and cause a wide spectrum of diseases for which we have limited therapies. To date, a few primary human stem cell-based models of the proximal airway have been reported for drug discovery but scaling them up to a higher throughput platform remains a significant challenge. As a result, most of the drug screening assays for respiratory viruses are performed on commercial cell line-based 2D cultures that provide limited translational ability.
View Article and Find Full Text PDFSurgery for chronic pyothorax after failed amplatzer closure of bronchopleural fistula.
J Cardiothorac Surg
January 2025
Department of Thoracic and Vascular Surgery, and Lung Transplantation, Marie-Lannelongue Hospital, Le Plessis-Robinson, France.
Background: Post-pneumonectomy bronchopleural fistula (BPF) is a life-threatening event whose treatment is not standardized.
Case Presentation: We report the management of a 28-year-old patient with a 3-year history of BPF complicating right pneumonectomy for congenital emphysema. Despite closure by an Amplatzer device, the patient had chronic pyothorax and severely deteriorated general health and quality of life.
Pathogen delivery route impacts disease severity in experimental Mycoplasma ovipneumoniae infection of domestic lambs.
Vet Res
January 2025
Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT, USA.
M. ovipneumoniae is a respiratory pathogen that can cause mild to moderate pneumonia and reduced productivity in domestic lambs. However, studies on both natural and experimental M.
View Article and Find Full Text PDFDistribution of Airway Findings in ANCA-Associated Vasculitis: A 20-Year Observational Analysis.
Diagnostics (Basel)
December 2024
Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Jacksonville, FL 32224, USA.
Pulmonary involvement is commonly observed in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), presenting with manifestations such as diffuse alveolar hemorrhage, inflammatory infiltrates, pulmonary nodules, and tracheobronchial disease. We aimed to identify distinct subgroups of tracheobronchial disease patterns in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) using latent class analysis (LCA), and to evaluate their clinical characteristics and outcomes. We conducted a retrospective cohort study using electronic medical records of patients aged >18 years diagnosed with AAV and tracheobronchial disease between 1 January 2002 and 6 September 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!